Mechanistically, ibrutinib or acalabrutinib potently inhibits BTK phosphorylation and its downstream oncogenic pathways such as the PI3K-mTOR and MEK/MAPK pathways, resulting in impaired tumorigenicity of these tumor cells (30, 31, 78, 80–82). The gene discussed is BTK; the disease is neoplasm.